HomeNewsBusinessMarketsBroader long-term India story intact; like pharma, NBFCs: UBS

Broader long-term India story intact; like pharma, NBFCs: UBS

The broader long-term India story is fairly robust and remains intact. So long-term investors need not worry, but shorter-term, the market is richly valued, said Gautam Chhaochharia, Head-India Research, UBS Securities.

September 24, 2016 / 14:38 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

As a base case, we do not expect a strong recovery for the Indian economy but the market expects so, is the word coming in from Gautam Chhaochharia, Head-India Research, UBS Securities.

However, the broader long-term India story is fairly robust and remains intact, says Chhaochharia in an interview to CNBC-TV18. So long-term investors need not worry, but shorter-term, the market is richly valued.

Story continues below Advertisement

For the market per se, as a base case, the house has a year-end target on Nifty at 8000 and an upside target of 8,800. Base case for 2017-end, the target is 9,400, he adds.

According to him, if the market is expecting a good recovery then spaces like NBFCs are likely to do even better because even when recovery wasn't good, they had delivered good growth and return on equities. He says the house has a overweight on non-banking financials (NBFCs), However they are no longer attractive on absolute valuation terms but on relative terms they are still good.